Rapid downregulation of cyclin D1 induced by geranylgeranoic acid in human hepatoma cells

Nutrition and Cancer

Volumn 64, Issue 3, 2012, Pages 473-480

  Shimonishi, Shohei ^a   Muraguchi, Takashi ^a   Mitake, Maiko ^a   Sakane, Chiharu ^a   Okamoto, Kyoko ^a   Shidoji, Yoshihiro ^a  

^a UNIVERSITY OF NAGASAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN D1; GERANYLGERANOIC ACID; RETINOBLASTOMA PROTEIN; SERINE; UNCLASSIFIED DRUG;

ARTICLE; CELL FRACTIONATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LIVER CELL CARCINOMA; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; WESTERN BLOTTING;

CELL CYCLE; CELL LINE, TUMOR; CYCLIN D1; DITERPENES; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LEUPEPTINS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84859735318     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.655401     Document Type: Article

References (49)

1. Freemantle, S J, Guo, Y, and, Dmitrovsky, E. 2009. Retinoid chemoprevention trials: cyclin D1 in the crosshairs. Cancer Prev Res (Phila Pa), 2: 3-6.
2. Kim, J K, and, Diehl, J A. 2009. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol, 220: 292-296.
3. Piechocki, M P, Yoo, G H, Dibbley, S K, and, Lonardo, F. 2007. Breast cancer expressing the activated her2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the her2/neu. Cancer Res, 67: 6825-6843. (Pubitemid 47105530)
4. Papadimitrakopoulou, V, Izzo, J G, Liu, D D, Meyers, J, Ceron, TL. 2009. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila Pa), 2: 14-21.
5. Izzo, J G, Wu, T T, Wu, X, Ensor, J, Luthra, R. 2007. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol, 25: 698-707. (Pubitemid 350002926)
6. Lippman, S M, Lee, J S, Lotan, R, Hittelman, W, Wargovich, M J. 1990. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst, 82: 555-560. (Pubitemid 20115445)
7. Papadimitrakopoulou, V A, Lee, J J, William, W N Jr., Martin, JW, Thomas, M. 2009. Randomized trial of 13- cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol, 27: 599-604.
8. Langenfeld, J, Kiyokawa, H, Sekula, D, Boyle, J, and, Dmitrovsky, E. 1997. Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism. Proc Natl Acad Sci U S A, 94: 12070-12074. (Pubitemid 27467844)
9. Dragnev, K H, Feng, Q, Ma, Y, Shah, SJ, Black, C. 2007. Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res, 174: 235-243.
10. Muto, Y, Moriwaki, H, and, Saito, A. 1999. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med, 340: 1046-1047. (Pubitemid 29157643)
11. Muto, Y, Moriwaki, H, Ninomiya, M, Adachi, S, Saito, A. 1996. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med, 334: 1561-1567. (Pubitemid 26177483)
12. Larson, R S, and, Tallman, M S. 2003. Retinoic acid syndrome: Manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol, 16: 453-461.
13. Ortega, J J, Madero, L, Martin, G, Verdeguer, A, Garca, P. 2005. Treatment with all- trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the pethema group. J Clin Oncol, 23: 7632-7640. (Pubitemid 46291827)
14. Shimizu, M, Suzui, M, Deguchi, A, Lim, JT, Xiao, D. 2004. Synergistic effects of acyclic retinoid and osi-461 on growth inhibition and gene expression in human hepatoma cells. Clin Cancer Res, 10: 6710-6721. (Pubitemid 39346569)
15. Shimizu, M, Suzui, M, Deguchi, A, Lim, J T, and, Weinstein, I B. 2004. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res, 10: 1130-1140. (Pubitemid 38198915)
16. Suzui, M, Sunagawa, N, Chiba, I, Moriwaki, H, and, Yoshimi, N. 2006. Acyclic retinoid, a novel synthetic retinoid, induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle- and differentiation-related molecules in human colon carcinoma cells. Int J Oncol, 28: 1193-1199.
17. Shidoji, Y, and, Ogawa, H. 2004. Natural occurrence of cancer-preventive geranylgeranoic acid in medicinal herbs. J Lipid Res, 45: 1092-1103. (Pubitemid 38679505)
18. Moriwaki, H, Muto, Y, Ninomiya, M, Kawai, K, Suzuki, Y. 1988. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3-methyl-n, n-dimethyl-4-aminoazobenzene. Gastroenterol Jpn, 23: 546-552. (Pubitemid 18264785)
19. Muto, Y, Moriwaki, H, and, Shiratori, Y. 1998. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Digestion, 59 (Suppl 2): 89-91. (Pubitemid 28372184)
20. Muto, Y, Moriwaki, H, and, Omori, M. 1981. In vitro binding affinity of novel synthetic polyprenoids (polyprenoic acids) to cellular retinoid-binding proteins. Gann, 72: 974-977. (Pubitemid 12172470)
21. Yamada, Y, Shidoji, Y, Fukutomi, Y, Ishikawa, T, Kaneko, T. 1994. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog, 10: 151-158. (Pubitemid 24257510)
22. Shidoji, Y, Nakamura, N, Moriwaki, H, and, Muto, Y. 1997. Rapid loss in the mitochondrial membrane potential during geranylgeranoic acid-induced apoptosis. Biochem Biophys Res Commun, 230: 58-63. (Pubitemid 27210242)
23. Freemantle, S J, Liu, X, Feng, Q, Galimberti, F, Blumen, S. 2007. Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem, 102: 869-877. (Pubitemid 350036927)
24. Feng, Q, Sekula, D, Muller, R, Freemantle, S J, and, Dmitrovsky, E. 2007. Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene, 26: 5098-5106. (Pubitemid 47206943)
25. Nakamura, N, Shidoji, Y, Moriwaki, H, and, Muto, Y. 1996. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via downregulation of transforming growth factor-alpha. Biochem Biophys Res Commun, 219: 100-104. (Pubitemid 26071610)
26. Shidoji, Y, Okamoto, K, Muto, Y, Komura, S, Ohishi, N. 2006. Prevention of geranylgeranoic acid-induced apoptosis by phospholipid hydroperoxide glutathione peroxidase gene. J Cell Biochem, 97: 178-187. (Pubitemid 43050189)
27. Kodaira, Y, Kusumoto, T, Takahashi, T, Matsumura, Y, Miyagi, Y. 2007. Formation of lipid droplets induced by 2,3-dihydrogeranylgeranoic acid distinct from geranylgeranoic acid. Acta Biochim Pol, 54: 777-782.
28. Alao, J P. 2007. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer, 6: 24
29. Zhang, Y J, Chen, S Y, Chen, C J, and, Santella, R M. 2002. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog, 33: 125-129. (Pubitemid 34113201)
30. Santra, M K, Wajapeyee, N, and, Green, M R. 2009. F-box protein FBXO31 mediates cyclin D1 degradation to induce g1 arrest after DNA damage. Nature, 459: 722-725.
31. Takahashi-Yanaga, F, and, Sasaguri, T. 2008. Gsk-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal, 20: 581-589. (Pubitemid 351241128)
32. Scita, G, Darwiche, N, Greenwald, E, Rosenberg, M, Politi, K. 1996. Retinoic acid downregulation of fibronectin and retinoic acid receptor alpha proteins in NIH-3T3 cells: blocks of this response by ras transformation. J Biol Chem, 271: 6502-6508. (Pubitemid 26095465)
33. Newman, R M, Mobascher, A, Mangold, U, Koike, C, Diah, S. 2004. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem, 279: 41504-41511. (Pubitemid 39313591)
34. Araki, H, Shidoji, Y, Yamada, Y, Moriwaki, H, and, Muto, Y. 1995. Retinoid agonist activities of synthetic geranylgeranoic acid derivatives. Biochem Biophys Res Commun, 209: 66-72.
35. Shimizu, M, Sakai, H, Shirakami, Y, Iwasa, J, Yasuda, Y. 2011. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/+Lepr(db) mice. Cancer Prev Res (Phila Pa), 4: 128-136.
36. Yu, Z, Willmarth, N E, Zhou, J, Katiyar, S, Wang, M. 2010. MicroRNA17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA, 107: 8231-8236.
37. Xia, W, Li, J, Chen, L, Huang, B, Li, S. 2010. MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells. Mol Cell Biochem, 344: 261-266.
38. Qin, X, Wang, X, Wang, Y, Tang, Z, Cui, Q. 2010. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A, 107: 3240-3244.
39. Chen, J, Feilotter, H E, Pare, G C, Zhang, X, Pemberton, JG. 2010. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol, 176: 2520-2529.
40. Jiang, Q, Feng, M G, and, Mo, Y Y. 2009. Systematic validation of predicted micrornas for cyclin D1. BMC Cancer, 9: 194
41. Sun, F, Fu, H, Liu, Q, Tie, Y, Zhu, J. 2008. Downregulation of CCND1 and CDK6 by mir-34a induces cell cycle arrest. FEBS Lett, 582: 1564-1568.
42. Davies, B P, and, Arenz, C. 2008. A fluorescence probe for assaying micro RNA maturation. Bioorg Med Chem, 16: 49-55.
43. Fan, S, Li, Y, Yue, P, Khuri, F R, and, Sun, S Y. 2010. The eIF4e/eIF4G interaction inhibitor 4eGI-1 augments trail-mediated apoptosis through c-FLIP downregulation and DR5 induction independent of inhibition of CAP-dependent protein translation. Neoplasia, 12: 346-356.
44. Jiao, W, Lin, H M, Datta, J, Braunschweig, T, Chung, JY. 2008. Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene, 27: 3156-3164. (Pubitemid 351693165)
45. Nishida, N, Fukuda, Y, Komeda, T, Kita, R, Sando, T. 1994. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res, 54: 3107-3110. (Pubitemid 24208910)
46. Huang, H L, Zheng, W L, Zhao, R, Zhang, B, and, Ma, W L. 2010. FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep, 24: 715-720.
47. Deane, N G, Parker, M A, Aramandla, R, Diehl, L, Lee, WJ. 2001. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res, 61: 5389-5395. (Pubitemid 32694916)
48. Arber, N, Doki, Y, Han, E K, Sgambato, A, Zhou, P. 1997. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res, 57: 1569-1574. (Pubitemid 27175576)
49. Weinstein, I B, Begemann, M, Zhou, P, Han, EK, Sgambato, A. 1997. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res, 3: 2696-2702. (Pubitemid 28133129)